Viridian Therapeutics Posts $24.7M in Lumvoa Revenue in First Quarter of Launch, Beating Estimates by Wide Margin

Viridian Therapeutics reported third-quarter 2026 financial results on November 4, with Lumvoa (veligrotug-vvze) generating $24.7 million in net product revenue in its first full quarter on the market, far exceeding analyst consensus estimates and representing a revenue surprise of more than 348%. More than 100 patients were on therapy with Lumvoa at the end of September, and CEO Steve Mahoney said the launch has "exceeded expectations," crediting the drug's clinical profile and commercial team execution.

The company posted a GAAP loss per share of $0.81, beating estimates by $0.21, while total net loss for the quarter was $101.2 million, up from $34.6 million in the same period a year earlier. The increase was driven by $57.6 million in selling, general and administrative expenses, more than double the $24.3 million recorded in Q3 2025, as Viridian built out its commercial infrastructure around the Lumvoa launch. Research and development expenses fell to $70.1 million from $86.3 million a year ago.

Viridian ended the quarter with $955.2 million in cash, cash equivalents, and marketable securities. The company said existing cash combined with anticipated future commercial revenues from Lumvoa and elegrobart, its next pipeline candidate, are expected to fund operations through profitability. A Biologics License Application for elegrobart remains on track for submission in Q1 2027.

On the pipeline front, Viridian said phase 1 data for VRDN-008 are on track for disclosure in Q4 2026, and VRDN-292, a potential best-in-class TSHR inhibitor, is expected to initiate a phase 1 clinical trial in patients in Q4 2026. Lumvoa received FDA approval in June 2026 for the treatment of thyroid eye disease regardless of disease activity or duration, making it the first approved TED therapy with labeling covering both active and chronic forms of the disease.